IC
EWTX icon

Ikarian Capital’s Edgewise Therapeutics EWTX Stock Holding History

Ikarian Capital’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-280,000
Closed -$6.16M – 159
2025
Q1 		$6.16M Buy
+280,000
New +$7.35M 0.76% 28
2024
Q1 		– Sell
-270,000
Closed -$2.95M – 157
2023
Q4 		$2.95M Buy
+270,000
New +$1.9M 0.28% 75

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Ikarian Capital's EWTX Position: Q2 2025 in Review

Ikarian Capital sold out of Edgewise Therapeutics (EWTX) in Q2 2025, closing a stake of 280,000 shares — an estimated $6.16M sold.

Ikarian Capital first reported a position in EWTX in Q4 2023 and held it in 2 quarters. The position peaked at $6.16M in Q1 2025. 178 funds tracked by Wall St. Rank hold EWTX as of Q2 2025.

  • Ikarian Capital reported no remaining Edgewise Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Ikarian Capital sold 280,000 Edgewise Therapeutics shares in Q2 2025, an estimated $6.16M.
  • Ikarian Capital first reported a position in Edgewise Therapeutics in Q4 2023 and held it in 2 quarters.
  • Ikarian Capital's Edgewise Therapeutics position peaked at $6.16M in Q1 2025.
  • 178 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2025.

Based on Ikarian Capital's 13F filing for Q2 2025, filed 14 Aug 2025.